Latest Candel Therapeutics News & Updates
See the latest news and media coverage for Candel Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of viral immunotherapies for cancer
candeltx.com- Headquarters
- Needham, United States
- Founded year
- 1999
- Company type
- Public company
- Number of employees
- 80–200
Latest news about Candel Therapeutics
Company announcements
-
Candel Therapeutics announces commercialization agreement with EVERSANA
EVERSANA provides integrated services for potential U.S. launch of aglatimagene besadenovec in localized prostate cancer following Q4 2026 BLA submission.
-
Candel Therapeutics reports extended survival in NSCLC trial
50% of patients survived beyond 24 months with CAN-2409. Median OS reached 25.4 months. Phase 3 trial planned for Q2 2026.
-
Candel Therapeutics reports Q4 and full-year 2025 financial results
Plans phase 3 NSCLC trial and prostate BLA in 2026. Secured $130M loan; cash lasts to Q1 2028.
-
Candel Therapeutics presents new data from Phase 3 trial
The presentation features extended follow-up results of aglatimagene besadenovec in localized prostate cancer at AUA 2026 Annual Meeting.
Media coverage
-
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer...
-
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA...
-
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate ...
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
-
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
Track Candel Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Candel Therapeutics competitors & trending companies
Browse news for competitors to Candel Therapeutics and other trending companies.
Humane Genomics
Aura Biosciences
Oncopeptides
Imugene
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB